




RealRate

PHARMACEUTICAL 2023

Marinus Pharmaceuticals INC
Rank 253 of 471



The relative strengths and weaknesses of Marinus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marinus Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Marinus Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 2.4% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	252,378
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,017
Liabilities, Non-Current	0
Other Assets	2,904
Other Compr. Net Income	0
Other Expenses	15,570
Other Liabilities	118,501
Other Net Income	107,033
Other Revenues	25,478
Property and Equipment	4,236
Research and Development	79,912
Selling, General and Administrative Expense	56,845

Output Variable	Value in 1000 USD
Assets	259,518
Liabilities	143,518
Expenses	152,327
Revenues	25,478
Stockholders Equity	116,000
Net Income	-19,816
Comprehensive Net Income	-19,816
BaseVar	343,937
ECR before LimitedLiability	116%
Economic Capital Ratio	242%